Edwards Lifesciences (EW)
NYSEHealth CareMedical DevicesSnapshot 2026-07-07
$94.82-0.38%
Close 2026-07-07 · 1-day change
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→NYSEHealth CareMedical DevicesSnapshot 2026-07-07
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady growth. The current thesis state is intact, supported by strong recent financial results and management's commitment to increasing sales and earnings guidance.
The market currently prices in a low level of fragility, reflecting justified expectations for the company's performance. There is a small expectations gap, indicating that the market has a moderate view of future growth compared to peers.
Fundamentals are likely to continue improving, as management is on track with its priorities to increase sales and earnings guidance. However, there is a moderate risk of missing estimates, especially given the recent performance of industry peers.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could provide a favorable environment for EW. Conversely, any negative guidance from these peers could impact EW's momentum.
Overall, the outlook for EW is cautiously optimistic, with strong management execution and a supportive sector backdrop. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, along with a setback from a rival that could enhance EW's market position. There are no significant threats noted at this time.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Strong TMTT sales growth will confirm the success of new therapies like EVOQUE and PASCAL. This is key for overall revenue growth.
Confirms:TMTT sales growth exceeds 35% year over year in 2026.
Disproves:TMTT sales growth is below 35% year over year in 2026.
Why it matters: Closing the $4.2 billion sale will improve Edwards' balance sheet. It will allow for more investments in structural heart innovations.
Confirms:The deal will close by the end of 2024. All approvals will be obtained.
Disproves:The deal will not close. This is due to regulatory issues or other problems.
Why it matters: The new CFO's plans could influence Edwards' financial strategy and growth outlook.
Confirms one read:The new CFO announces a clear strategic plan that aligns with growth goals.
Confirms the other:The new CFO's initiatives are vague or do not align with growth expectations.
Why it matters: TAVR sales growth is key for Edwards' overall performance. Changes in guidance can impact investor sentiment.
Confirms one read:TAVR sales growth guidance is raised above 9% for 2026.
Confirms the other:TAVR sales growth guidance is lowered below 7% for 2026.
Why it matters: The new CFO may bring changes to financial strategy that could affect growth and investor confidence.
Confirms one read:New financial strategy changes were announced. These changes match the growth goals.
Confirms the other:There are negative effects on financial strategy. This is reported under the new CFO.
Why it matters: The PROGRESS trial results will show how well TAVR works for moderate aortic stenosis. Good results could lead to more use of TAVR.
Confirms:Positive results from the PROGRESS trial presented at the TCT conference.
Disproves:Negative results from the PROGRESS trial or no presentation at the TCT conference.
Why it matters: A favorable CMS decision could improve access to TAVR therapy, boosting sales. This is critical for expanding the patient base.
Confirms:CMS makes a positive decision on TAVR coverage.
Disproves:CMS keeps or denies changes to TAVR coverage.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Sales growth results will indicate if the company maintains its upward trend. This is crucial for investor confidence.
Confirms:Q2 2026 sales growth exceeds the guidance of 9% to 11%.
Disproves:Q2 2026 sales growth falls below the guidance range.